Clinical Evidence for Repurposed Generic Drugs in Cancer
Many FDA-approved drugs developed for non-cancer indications have been studied for new uses in oncology. When these drugs go off-patent, the supporting clinical evidence is often left fragmented and difficult to evaluate.
Reboot Rx identifies repurposed generic drugs with clinical evidence for use in cancer, assesses where further study is warranted, and develops open, transparent resources to support clinical awareness and informed discussion. Our first resource covers 5-alpha reductase inhibitors in prostate cancer, with more disease areas in development.
Evidence Resource: 5-Alpha Reductase Inhibitors (5-ARIs) in Prostate Cancer
Relevant for: Urologists and clinicians managing prostate cancer with active surveillance
Finasteride and dutasteride have been evaluated in multiple clinical studies for their impact on disease progression and related outcomes in patients with prostate cancer on active surveillance. This resource consolidates the evidence.
What’s inside:
Summaries and key outcomes from 2 randomized controlled trials, 3 meta-analyses, and 10 observational studies
Full references to the underlying literature
Safety considerations
Mechanism of action
Information on drug access
Contribute Clinical Insight
Our first clinician resource focuses on prostate cancer, but we're expanding to other indications where generic drugs show strong repurposing potential. If you’re interested in drug repurposing, we value clinical input from all specialties.
Share your perspective
We welcome clinical insight on treatment selection, implementation opportunities, and real-world outcomes.
Collaborate
Participate in pilots, real-world data efforts, and health system partnerships.
Reboot Rx surfaces and organizes evidence. The 5-ARI evidence resource is for informational purposes only and is not intended to provide medical advice.